18:12 IST
BSE
Other Announcement
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs discloses share transactions by designated persons and an employee welfare trust under PIT regulations.
Dr. Lal Pathlabs Ltd
- Share price
- ₹1,948.90
- Market cap
- ₹32,712 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 60.4×Sector 53.1×
- Promoter holding
- 53.19%-0.02% QoQ
- FII holding
- 17.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Acquisition 10Other Announcement 6Merger & Restructuring 6Financial Results 6Employee Stock Options 5Earnings Call 4Dividend 4Board Meeting Date 3Results Update 2Legal & Regulatory 2Board Meeting Outcome 2Annual General Meeting 2Management Change 1Capital Structure Change 1Business Update 1Annual Report 1
Time
6 announcements with these filters
17:46 IST
BSE
Other Announcement
Dr. Lal Pathlabs Other Announcement
Designated persons at Dr. Lal PathLabs Ltd disclosed three equity trades totaling Rs. 0.50 Crore, as mandated under Insider Trading regulations.
- Value
- ₹0.50 Cr
17:51 IST
BSE
Other Announcement
Dr. Lal Pathlabs Other Announcement
Designated persons and the employee welfare trust of Dr. Lal PathLabs Ltd disclosed share transactions under PIT Regulations. These trades involve ESOP-related activities and market sales.
16:55 IST
BSE
Other Announcement
Dr. Lal Pathlabs Other Announcement
Designated Person Abhishek Maini acquired 500 equity shares via ESOP and subsequently sold 500 shares. This is a routine regulatory disclosure of personal trading activity.
11:26 IST
BSE
Other Announcement
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details the distribution of equity shares across various investor categories.
20:02 IST
BSE
Other Announcement
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs has sent letters to shareholders without registered emails. The communication provides a web-link to access the Annual Report for FY 2025-26.